A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe

A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe

Abstract Background DCZ3301, a novel aryl-guanidino compound previously reported by our group, exerts cytotoxic effects against multiple myeloma (MM), diffused large B cell lymphoma (DLBCL), and T-cell leukemia/lymphoma. However, the underlying mechanism of its action remains unknown. Methods We gen...

Full description

Bibliographic Details
Main Authors: Liangning Hu, Bo Li, Gege Chen, Dongliang Song, Zhijian Xu, Lu Gao, Mengyu Xi, Jinfeng Zhou, Liping Li, Hui Zhang, Qilin Feng, Yingcong Wang, Kang Lu, Yumeng Lu, Wenxuan Bu, Houcai Wang, Xiaosong Wu, Weiliang Zhu, Jumei Shi
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Multiple myeloma
Drug-resistance
DNA damage response
Cell cycle
Online Access:http://link.springer.com/article/10.1186/s13046-020-01597-9

Internet

http://link.springer.com/article/10.1186/s13046-020-01597-9

Similar Items